LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Definitive Healthcare to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 02, 2025 | Last Trade: US$3.81 0.22 -5.46

FRAMINGHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and Chief Financial Officer, Casey Heller, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference.

The Definitive Healthcare presentation is scheduled for Tuesday, September 9, 2025, at 9:15 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-277-1251

Media Contact:
Bethany Swackhamer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page